Affordable Access

deepdyve-link
Publisher Website

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.

Authors
  • Gerecitano, John F
  • Stephenson, Joe J
  • Lewis, Nancy L
  • Osmukhina, Anna
  • Li, Jianguo
  • Wu, Kaida
  • You, Zhiping
  • Huszar, Dennis
  • Skolnik, Jeffrey M
  • Schwartz, Gary K
Type
Published Article
Journal
Investigational New Drugs
Publisher
Springer-Verlag
Publication Date
Apr 01, 2013
Volume
31
Issue
2
Pages
355–362
Identifiers
DOI: 10.1007/s10637-012-9821-y
PMID: 22615058
Source
Medline
License
Unknown

Abstract

AZD4877 is generally well-tolerated with pharmacodynamic evidence of target inhibition in circulating PBMCs.

Report this publication

Statistics

Seen <100 times